文献速递肝病

第三剂COVID-19 mRNA疫苗似可克服肝硬化患者的疫苗低反应性

Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis.
PubMed 文献 · J Hepatol · 2022-09-28

该回顾性队列研究纳入接受2或3剂COVID-19 mRNA疫苗的肝硬化患者,将13041例接种3剂者与13041例接种2剂者进行倾向性评分匹配,研究期间为2021年7月18日至2022年2月11日。接种第三剂与COVID-19减少80.7%、有症状COVID-19减少80.4%、中度及以上COVID-19减少80%、重度或危重度COVID-19减少100%、COVID-19相关死亡减少100%相关。结论认为第三剂或可克服肝硬化人群的疫苗低反应性。

要点

  • 肝硬化患者接种第三剂mRNA疫苗与COVID-19风险降低80.7%相关。
  • 第三剂与重度或危重度COVID-19及COVID-19相关死亡均减少100%相关。
  • BNT162b2第三剂及代偿期肝硬化者的COVID-19下降幅度更大。

核心结论

  • 接种第三剂COVID-19 mRNA疫苗与肝硬化患者COVID-19更显著下降相关,提示第三剂或可克服该人群的疫苗低反应性。

研究设计与样本

  • 回顾性队列研究,纳入在退伍军人健康管理局接受2或3剂COVID-19 mRNA疫苗的肝硬化患者。
  • 接种3剂者13041例与接种2剂对照者13041例进行倾向性评分匹配,研究期间为2021年7月18日至2022年2月11日,当时B.1.617.2(delta)和B.1.1.529(omicron)为主要流行变异株。

主要发现

  • 接种第三剂与COVID-19减少80.7%相关(95%CI 39.2-89.1,p<0.001)。
  • 接种第三剂与有症状COVID-19减少80.4%相关。
  • 接种第三剂与中度、重度或危重度COVID-19减少80%相关(95%CI 34.5-87.6%,p=0.005)。
  • 接种第三剂与重度或危重度COVID-19减少100%相关(95%CI 99.2-100.0,p=0.01)。
  • 接种第三剂与COVID-19相关死亡减少100%相关(95%CI 99.8-100.0,p=0.007)。

临床怎么用

  • 作者认为这些发现支持肝硬化患者接种第三剂mRNA疫苗的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cirrhosis is associated with immune dysregulation and hyporesponsiveness to several vaccines including those against COVID-19. Our aim was to compare outcomes between patients with cirrhosis who received 3 doses of either the Pfizer BNT162b2 mRNA or Moderna mRNA-1273 vaccines to a propensity-matched control group of patients at similar risk of infection who received 2 doses. METHODS: This was a retrospective cohort study of patients with cirrhosis who received 2 or 3 doses of a COVID-19 mRNA vaccine at the Veterans Health Administration. Participants who received 3 doses of the vaccine (n = 13,041) were propensity score matched with 13,041 controls who received 2 doses, and studied between July 18, 2021 and February 11, 2022, when B.1.617.2 (delta) and B.1.1.529 (omicron) were the predominant variants. Outcomes were aggregated as all cases with COVID-19, symptomatic COVD-19, with at least moderate COVID-19, or severe or critical COVID-19. RESULTS: Receipt of the third dose of a COVID-19 mRNA vaccine was associated with an 80.7% reduction in COVID-19 (95% CI 39.2-89.1, p <0.001), an 80.4% reduction in symptomatic COVID-19, an 80% reduction in moderate, severe or critical COVID-19, (95% CI 34.5-87.6%, p = 0.005), a 100% reduction in severe or critical COVID-19 (95% CI 99.2-100.0, p = 0.01), and a 100% reduction in COVID-19-related death (95% CI 99.8-100.0, p = 0.007). The magnitude of reduction in COVID-19 was greater with the third dose of BNT 162b2 than mRNA-1273 and among participants with compensated rather than decompensated cirrhosis. CONCLUSIONS: Administration of a third dose of a COVID-19 mRNA vaccine was associated with a more significant reduction in COVID-19 in patients with cirrhosis than in the general population, suggesting that the third dose can overcome vaccine hyporesponsiveness in this population. LAY SUMMARY: Cirrhosis is associated with decreased responsiveness to several vaccines, including those against COVID-19. In this study of 26,082 participants with cirrhosis during the delta and omicron surge, receipt of the third dose of the vaccine was associated with an 80% reduction in COVID-19, a 100% reduction in severe/critical COVID-19, and a 100% reduction in COVID-19-related death. These findings support the importance of a third dose of mRNA vaccine among patients with cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. John BV, Ferreira RD, Doshi A, et al. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. J Hepatol. 2022. PMID: 36181987. doi:10.1016/j.jhep.2022.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。